Amicus Therapeutics (FOLD) Stock Price, News & Analysis

$10.71
-0.11 (-1.02%)
(As of 04/23/2024 ET)
Today's Range
$10.68
$10.92
50-Day Range
$10.33
$14.00
52-Week Range
$9.70
$14.57
Volume
5.09 million shs
Average Volume
2.46 million shs
Market Capitalization
$3.16 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.00

Amicus Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
86.7% Upside
$20.00 Price Target
Short Interest
Bearish
11.00% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.28
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$662,605 Sold Last Quarter
Proj. Earnings Growth
3,300.00%
From $0.01 to $0.34 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.89 out of 5 stars

Medical Sector

197th out of 909 stocks

Pharmaceutical Preparations Industry

77th out of 424 stocks

FOLD stock logo

About Amicus Therapeutics Stock (NASDAQ:FOLD)

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

FOLD Stock Price History

FOLD Stock News Headlines

Amicus Therapeutics Becomes Oversold (FOLD)
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
FOLD Jul 2024 12.000 call
FOLD Oct 2024 12.000 call
FOLD Jan 2025 12.000 put
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
FOLD Jul 2024 9.000 put
Q4 2023 Amicus Therapeutics Inc Earnings Call
Buy Rating Affirmed for Amicus with Strong Growth and Promising Outlook
See More Headlines
Receive FOLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/24/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:FOLD
CUSIP
03152W10
Employees
517
Year Founded
2002

Price Target and Rating

Average Stock Price Target
$20.00
High Stock Price Target
$22.00
Low Stock Price Target
$19.00
Potential Upside/Downside
+86.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-151,580,000.00
Pretax Margin
-37.59%

Debt

Sales & Book Value

Annual Sales
$399.36 million
Book Value
$0.55 per share

Miscellaneous

Free Float
289,180,000
Market Cap
$3.16 billion
Optionable
Optionable
Beta
0.75

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

FOLD Stock Analysis - Frequently Asked Questions

Should I buy or sell Amicus Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FOLD shares.
View FOLD analyst ratings
or view top-rated stocks.

What is Amicus Therapeutics' stock price target for 2024?

3 analysts have issued 1 year price objectives for Amicus Therapeutics' stock. Their FOLD share price targets range from $19.00 to $22.00. On average, they predict the company's share price to reach $20.00 in the next year. This suggests a possible upside of 86.7% from the stock's current price.
View analysts price targets for FOLD
or view top-rated stocks among Wall Street analysts.

How have FOLD shares performed in 2024?

Amicus Therapeutics' stock was trading at $14.19 at the start of the year. Since then, FOLD stock has decreased by 24.5% and is now trading at $10.71.
View the best growth stocks for 2024 here
.

When is Amicus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our FOLD earnings forecast
.

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) issued its quarterly earnings data on Wednesday, February, 28th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by $0.05. The biopharmaceutical company had revenue of $115.08 million for the quarter, compared to the consensus estimate of $115.11 million. Amicus Therapeutics had a negative net margin of 37.96% and a negative trailing twelve-month return on equity of 119.46%.

What is John F. Crowley's approval rating as Amicus Therapeutics' CEO?

21 employees have rated Amicus Therapeutics Chief Executive Officer John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among the company's employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amicus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

Who are Amicus Therapeutics' major shareholders?

Amicus Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Rice Hall James & Associates LLC (0.35%), Los Angeles Capital Management LLC (0.04%), Diversified Trust Co (0.02%), Allspring Global Investments Holdings LLC (0.01%) and Fulton Bank N.A. (0.00%). Insiders that own company stock include Bradley L Campbell, Bradley L Campbell, Burke W Whitman, Burke W Whitman, Daphne Quimi, David Michael Clark, Ellen Rosenberg, Ellen Rosenberg, Jeff Castelli, John F Crowley, John F Crowley, Lynn Dorsey Bleil, Margaret G Mcglynn, Michael Raab and Samantha Prout.
View institutional ownership trends
.

How do I buy shares of Amicus Therapeutics?

Shares of FOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FOLD) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners